Latest Insider Transactions at Crinetics Pharmaceuticals, Inc. (CRNX)
This section provides a real-time view of insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Crinetics Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Crinetics Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2023
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+50.0%
|
-
|
|
Jun 16
2023
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+35.29%
|
-
|
|
Jun 08
2023
|
Coelho Rogerio Vivaldi |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$110,000
$22.06 P/Share
|
|
Apr 05
2023
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
8,212
-64.6%
|
$131,392
$16.15 P/Share
|
|
Apr 03
2023
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,288
-25.22%
|
$64,320
$15.98 P/Share
|
|
Mar 16
2023
|
Richard Scott Struthers President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,628
-3.56%
|
$78,676
$17.12 P/Share
|
|
Mar 16
2023
|
Marc Wilson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-1.55%
|
$28,322
$17.12 P/Share
|
|
Mar 16
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,410
-1.6%
|
$23,970
$17.12 P/Share
|
|
Mar 16
2023
|
Jeff E. Knight Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
587
-1.68%
|
$9,979
$17.12 P/Share
|
|
Mar 16
2023
|
Alan Seth Krasner Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-3.84%
|
$28,679
$17.12 P/Share
|
|
Mar 01
2023
|
James Hassard Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+50.0%
|
-
|
|
Mar 01
2023
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,600
+21.09%
|
-
|
|
Mar 01
2023
|
Alan Seth Krasner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,500
+30.71%
|
-
|
|
Mar 01
2023
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+20.93%
|
-
|
|
Mar 01
2023
|
Marc Wilson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
24,200
+18.34%
|
-
|
|
Mar 01
2023
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,500
+45.75%
|
-
|
|
Mar 01
2023
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
61,650
+32.14%
|
-
|
|
Feb 01
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-4.61%
|
$59,394
$19.59 P/Share
|
|
Jan 25
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,336
-10.95%
|
$175,056
$21.07 P/Share
|
|
Jan 17
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.94%
|
$56,268
$18.0 P/Share
|
|
Jan 03
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.79%
|
$56,268
$18.35 P/Share
|
|
Dec 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.65%
|
$50,016
$16.0 P/Share
|
|
Dec 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.55%
|
$53,142
$17.84 P/Share
|
|
Nov 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.43%
|
$56,268
$18.72 P/Share
|
|
Nov 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.31%
|
$56,268
$18.52 P/Share
|
|
Oct 17
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.21%
|
$53,142
$17.73 P/Share
|
|
Oct 12
2022
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+13.94%
|
$11,100
$1.91 P/Share
|
|
Oct 10
2022
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+50.0%
|
-
|
|
Oct 03
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.11%
|
$59,394
$19.64 P/Share
|
|
Sep 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,168
-3.98%
|
$87,528
$21.01 P/Share
|
|
Sep 07
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,042
-0.98%
|
$21,882
$21.0 P/Share
|
|
Sep 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-2.87%
|
$56,268
$18.59 P/Share
|
|
Jul 26
2022
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,152
-18.88%
|
$23,040
$20.7 P/Share
|
|
Jul 13
2022
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
5,700
-31.26%
|
$114,000
$20.96 P/Share
|
|
Jul 13
2022
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+23.81%
|
$5,700
$1.45 P/Share
|
|
May 20
2022
|
Stephen F. Betz Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
1,336
+1.21%
|
$14,696
$11.02 P/Share
|
|
May 20
2022
|
Jeff E. Knight Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,152
+15.88%
|
$19,584
$17.44 P/Share
|
|
May 02
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,247
-2.93%
|
$64,940
$20.1 P/Share
|
|
Apr 18
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,664
-4.86%
|
$141,600
$25.81 P/Share
|
|
Apr 18
2022
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
157,515
+2.88%
|
$3,465,330
$22.22 P/Share
|
|
Apr 13
2022
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
138,643
-5.6%
|
$3,604,718
$26.49 P/Share
|
|
Apr 05
2022
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
21,357
-2.4%
|
$533,925
$25.34 P/Share
|
|
Apr 04
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,000
-7.17%
|
$207,000
$23.97 P/Share
|
|
Apr 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,164
-3.21%
|
$87,444
$21.8 P/Share
|
|
Mar 31
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,164
-3.11%
|
$87,444
$21.06 P/Share
|
|
Mar 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,123
-2.28%
|
$56,214
$18.94 P/Share
|
|
Mar 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,123
-2.23%
|
$59,337
$19.73 P/Share
|
|
Mar 01
2022
|
Ajay Madan Chief Development Officer |
BUY
Open market or private sale
|
Direct |
9,000
+4.84%
|
$171,000
$19.88 P/Share
|
|
Feb 28
2022
|
Alan Seth Krasner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,250
+38.71%
|
-
|
|
Feb 28
2022
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+10.54%
|
-
|